Thrombin Receptor Agonist Peptide–Induced Platelet Aggregation Is Reduced in Patients Receiving Dabigatran | Zendy

František Neháj | Zendy; Juraj Sokol | Zendy; Michal Mokáň | Zendy; Jela Ivanková | Zendy; Maros Mokan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Thrombin Receptor Agonist Peptide–Induced Platelet Aggregation Is Reduced in Patients Receiving Dabigatran

Author(s) -

František Neháj,

Juraj Sokol,

Michal Mokáň,

Jela Ivanková,

Maros Mokan

Publication year - 2017

Publication title -

clinical and applied thrombosis/hemostasis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.643

H-Index - 53

eISSN - 1938-2723

pISSN - 1076-0296

DOI - 10.1177/1076029617713871

Subject(s) - dabigatran , medicine , platelet , agonist , thrombin , coagulation , direct thrombin inhibitor , thrombin receptor , pharmacology , platelet activation , atrial fibrillation , thrombin time , anesthesia , cardiology , receptor , warfarin , partial thromboplastin time

The availability of direct oral anticoagulants has caused a paradigm shift in thrombosis management. The direct thrombin inhibitor dabigatran seems to obstruct tenase complex by inhibiting thrombin generated in the initial phase and feed back to the amplification phase of cell-based coagulation reactions. However, it is still not fully understood if and how dabigatran impact platelet function. This observational study aimed to assess in vitro platelet function in patients with atrial fibrillation receiving dabigatran. Platelet aggregability was tested with platelet-rich plasma using platelet aggregometry (PACKS-4 aggregometer). Blood samples were stimulated with thrombin receptor agonist peptide (TRAP; 32 μmol/L).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research